In conclusion, treatment with EVE + EXE provided a clinically meaningful PFS benefit in this heavily pre-treated population of Chinese patients with ER + , HER2- breast cancer, further validating the clinical benefit reported in the global BOLERO-2 trial. This evidence concerns the gene ESR1 and breast cancer.